نتایج جستجو برای: prodrug

تعداد نتایج: 4411  

2017
Dhrubo Jyoti Sen

Our goal is to perform in-vitro biotransformation of Prodrugs of ibuprofen+paracetamol, diclofenac sodium+paracetamol and ibuprofen+diclofenac sodium by acidic and alkaline hydrolysis of both ester (–COO–) and amide (–CONH–) linkages into free drugs and chromatographically separation of their Rt in HPLC. Since both ester (–COO–) and amide (–CONH–) linkages are susceptible to hydrolysis in both ...

2016
Hui Liu Lei Yang Hui-Jun Wu Kui-Hao Chen Feng Lin Gang Li Hai-Ying Sun Guo-Sheng Xiao Yan Wang Gui-Rong Li

The morbidity and mortality of patients with ischemic cardiomyopathy resulted from ischemia/reperfusion injury are very high. The present study investigates whether our previously synthesized water-soluble phosphate prodrug of acacetin was cardioprotective against ischemia/reperfusion injury in an in vivo rat model. We found that intravenous administration of acacetin prodrug (10 mg/kg) decreas...

2011
Shalmali Pradhan M. N. Nagashri K. S. Gopinath Arun Kumar

Oral Squamous Cell Carcinoma (OSCC) has a very flagitious treatment regime. A prodrug approach is thought to aid in targeting chemotherapy. CYP1B1, a member of cytochrome P450 family, has been implicated in chemical carcinogenesis. There exists a general accordance that this protein is overexpressed in a variety of cancers, making it an ideal candidate for a prodrug therapy. The activation of t...

Journal: :Cancer research 2007
Guy Ungerechts Christoph Springfeld Marie E Frenzke Johanna Lampe Patrick B Johnston William B Parker Eric J Sorscher Roberto Cattaneo

Combination chemotherapy regimen incorporating CD20 antibodies are commonly used in the treatment of CD20-positive non-Hodgkin's lymphoma (NHL). Fludarabine phosphate (F-araAMP), cyclophosphamide, and CD20 antibodies (Rituximab) constitute the FCR regimen for treating selected NHL, including aggressive mantle cell lymphoma (MCL). As an alternative to the CD20 antibody, we generated a CD20-targe...

Journal: :Cancer research 2001
A Trouet A Passioukov K Van derpoorten A M Fernandez J Abarca-Quinones R Baurain T J Lobl C Oliyai D Shochat V Dubois

Oligopeptidic derivatives of anthracyclines unable to penetrate cells were prepared and screened for their stability in human blood and their reactivation by peptidases secreted by cancer cells. N-beta-alanyl-L-leucyl-L-alanyl-L-leucyl-doxorubicin was selected as a new candidate prodrug. The NH2-terminal beta-alanine allows a very good blood stability. A two-step activation by peptidases found ...

Journal: :The Journal of pharmacology and experimental therapeutics 1999
A J Versluis E T Rump P C Rensen T J van Berkel M K Bijsterbosch

Many tumors express elevated levels of low-density lipoprotein (LDL) receptors. Therefore, native LDL and synthetic LDL-like particles have been proposed as carriers for antineoplastic drugs. We demonstrated earlier that small apolipoprotein E (apoE)-exposing liposomes were specifically recognized by the LDL receptor. In this study, we incorporated a lipophilic derivative of daunorubicin (LAD) ...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2018
Chun Chen Zhihao Wang Zhentao Zhang Xia Liu Seong Su Kang Ying Zhang Keqiang Ye

The BDNF mimetic compound 7,8-dihydroxyflavone (7,8-DHF), a potent small molecular TrkB agonist, displays prominent therapeutic efficacy against Alzheimer's disease (AD). However, 7,8-DHF has only modest oral bioavailability and a moderate pharmacokinetic (PK) profile. To alleviate these preclinical obstacles, we used a prodrug strategy for elevating 7,8-DHF oral bioavailability and brain expos...

Journal: :Biochemical Society transactions 1995
D C Blakey P J Burke D H Davies R I Dowell R G Melton C J Springer A F Wright

34 Hale, G., Dyer, M. J., Clark, M. R., Phillips, J. M., Marcus, R., Riechmann, L., Winter, G. and Waldmann, H. (1988) Lancet 2, 1394-1395 35 Dyer, M. J. S., Hale, G., Hayhoe, F. G. C. and Waldmann, H. (1989) Blood 73, 1431-1439 36 Waldmann, T. A., Goldman, C. K., Bongiovanni, K. F. et al. (1988) Blood 72, 1805-1816 37 Cheung, N-K., Lazarus, H., Miraldi, F. D. et al. (1987) J. Clin. Oncol. 5, 1...

2016
Ziyuan Meng Quanxia Lv Jun Lu Houzong Yao Xiaoqing Lv Feng Jiang Aiping Lu Ge Zhang

Paclitaxel is an anti-tumor agent with remarkable anti-tumor activity and wide clinical uses. However, it is also faced with various challenges especially for its poor water solubility and low selectivity for the target. To overcome these disadvantages of paclitaxel, approaches using small molecule modifications and macromolecule modifications have been developed by many research groups from al...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید